Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E2

Michael G. Backlund, Jason R. Mann, Raymond N. DuBois

Research output: Contribution to journalArticlepeer-review

89 Scopus citations


Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE2, are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE2, promotes colon cancer.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
Issue numberSUPPL. 1
StatePublished - 2005
Externally publishedYes


  • 15-Hydroxyprostaglandin dehydrogenase
  • Colorectal cancer
  • Cyclooxygenase 2
  • Prostaglandin E

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E2'. Together they form a unique fingerprint.

Cite this